• linkedin
  • Increase Font
  • Sharebar

    ALG-1001: Turning off the machinery of angiogenesis

     

    Phase II study

    The previous phase II, stage 1 DME study results indicated that ALG-1001 monotherapy was not inferior to bevacizumab and showed 12-week durability compared with monthly bevacizumab treatment.

    The multicenter phase IIb stage 2 clinical trial evaluated the safety and efficacy of ALG-1001 compared with bevacizumab pre-treatment or combined with bevacizumab in 80 patients, 60% of whom had been treated chronically with anti-VEGF therapy.

    The study had 3 arms: administration of 0.5 mg or 1.0 mg of ALG-1001 with bevacizumab pretreatment, administration of 0.5 mg or 1.0 mg of ALG-1001 and bevacizumab combination therapy, and a bevacizumab control arm of 5 monthly injections. The primary endpoint was the mean best-corrected visual acuity (BCVA) at week 20 with 12 weeks off of ALG-1001 treatment versus every-4-week bevacizumab injections, Dr. Boyer recounted.

    At the 5-month follow-up evaluation, Dr. Boyer reported that the primary endpoint of BCVA non-inferiority was met. Regarding the 0.5-mg or 1.0-mg doses of ALG-1001 with the 1.25-mg dose of bevacizumab pretreatment, compared to the bevacizumab control, the mean BCVA showed non-inferiority through week 20.

    “The (ALG-1001) results were achieved after 1 treatment of 1.25 mg bevacizumab (week 0) followed by 3, 1.0-mg (ALG-1001) injections at weeks 1, 4, and 8 followed by 12 weeks off of the treatment, compared to 5 injections of bevacizumab administered every 4 weeks. The data showed the mean letter gain in BCVA was 7.1 for patients in the group treated with ALG-1001 and bevacizumab pre-treatment (sequential) group compared to 6.7 letters for patients in the monthly bevacizumab-treated control group.

    Importantly, no adverse effects related to ALG-1001 occurred.

    Clearing the VEGF burden

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow

    var script= ' ';